The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.